Business Wire

OR-AIRSHIP

27.10.2021 15:02:16 CEST | Business Wire | Press release

Share
Airship Unveils the Airship App Experience Platform, Making it Much Simpler and Faster for Brands to Capture More Business Value from Mobile Apps

Later today at Elevate 2021 , the mobile app experience company Airship will debut its next-generation App Experience Platform that makes it simple to create, measure and perfect in-app experiences crucial to onboarding app audiences, building user understanding for next-level personalization, and advancing monetization goals through a data-led approach. New innovations including Airship Tours, Airship Surveys and Airship Preference Center, give business users full control to easily create, automate and adapt rich, native app experiences for continuous onboarding and first-party and zero-party data collection without ongoing developer support or having to update apps in the App Store or Google Play.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005301/en/

“Mobile apps have become the preferred destination for customers due to simple, contextual interactions, faster transactions and streamlined experiences that elegantly span their digital and physical worlds, like click-and-collect, loyalty and subscription programs, and direct-to-consumer commerce to name a few,” said Brett Caine, CEO and president, Airship. “However, realizing the full business potential of apps is challenging with progress hampered by reliance on development resources and cyclical app updates that have left marketers, and the industry-at-large, approaching apps as another promotional channel rather than creating reciprocal value exchanges necessary for sustained relationships.”

Mobile app retention rates average only 28 percent after day one and 15 percent after the first week1 , yet app users produce 3.5X more revenue than other shoppers and they are 3X more likely to make a repeat purchase2 . First impressions are critical, and Airship Tours allows marketers and mobile product owners to easily create, edit and manage full-screen, interactive walkthroughs (up to 10 screens long) that showcase the value of the app and how to get started. Tours can drive onboarding, feature adoption, loyalty enrollment or any number of key milestone activities such as completing their profile, authenticating within the app, opting into notifications, setting preferences and more. Tours can be triggered based on customers’ real-time behaviors and attributes, enabling exceptionally relevant and personalized treatments, and real-time analytics that highlight ways to improve the experience and outcomes.

Airship Surveys allow marketers and mobile product owners to collect granular feedback from users while they are engaged with the app, gaining actionable insights to improve app experiences without developer involvement. Surveys can be targeted to customers based on their attributes and real-time behaviors, such as purchases, engagement with a new feature, abandoned carts or Tours completed, and resulting data can be analyzed by customer segments for more nuanced understanding and to target future campaigns. Pre-built survey templates for NPS and product feedback make it easy to get started.

Announced last month, Airship Preference Center now encompasses all re-engagement messaging channels (e.g., SMS and email), enabling customers to control the types of content they receive on different channels in one place. Marketers and mobile product owners can also take advantage of opt-in forms for SMS and email to place on their websites, and can see all channels a user has opted in to from lookups within the Airship App Experience Platform.

Availability

These new solutions will be available over the coming months. Brands interested in getting first access can request to join Airship’s special access program .

Airship is a Leader in “The Forrester Wave™: Mobile Engagement Automation, Q3 2020 ,” receiving the highest score in the Strategy category and the second highest score in the Current Offering category.

About Airship

No one knows more, does more, or cares more when it comes to helping brands master mobile app experiences than Airship. From the beginning of apps, we powered the first commercial messages and then expanded our data-led approach to all re-engagement channels (mobile wallet, SMS, email), app UX experimentation, proactive in-app conversations and now rich in-app experiences that business users can create and adapt on their own — with no ongoing developer support or app update required.

From the trillions of mobile app interactions we’ve powered for thousands of global brands, we’ve been there, and done that, lending our solutions and expertise to help apps become the pinnacle of elegant customer experiences and winning brand loyalty strategies. One could say Airship has one mission: to go where mobile will take your business.

For more information, visit www.airship.com , read our blog or follow us on Twitter , LinkedIn and Facebook .


1 Adjust "Mobile App Trends 2021: A Global Benchmark of App Performance"
2 eMarketer, “Frictionless Commerce,” May 21, 2020

Link:

ClickThru

Social Media:

https://www.facebook.com/airshipsocial/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release

Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release

£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release

Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int

Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release

Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'

Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release

Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye